我们的分析表明,行业实践的差异,例如,每种化合物使用的恢复动物数量支持首次人类临床试验,范围从0到超过100。is ‘default’ company practice or perceived regulatory expectation. By sharing data on 259 studies for 137 compounds (including 53 biologicals and 78 small molecules) we have identified that the use of recovery animals could be reduced by up to 66%, saving thousands of animals globally each year. Based on this we have developed recommendations that move away from a default approach to the inclusion of recovery animals and instead encourage science-based case-by-case consideration. This work has been published in调节性毒理学和药理学[[1]。